TY - JOUR
T1 - Lycopene used as Anti-inflammatory Nanodrug for the Treatment of Rheumathoid Arthritis
T2 - Animal assay, Pharmacokinetics, ABC Transporter and Tissue Deposition
AU - Moia, Vivian Meira
AU - Leal Portilho, Filipe
AU - Almeida Pádua, Tatiana
AU - Barbosa Corrêa, Luana
AU - Ricci-Junior, Eduardo
AU - Cruz Rosas, Elaine
AU - Magalhaes Rebelo Alencar, Luiciana
AU - Savio Mendes Sinfronio, Francisco
AU - Sampson, Angelina
AU - Hussain Iram, Surtaj
AU - Alexis, Frank
AU - de OliveiraHenriques, Maria das Graccedilas Muller
AU - Santos-Oliveira, Ralph
N1 - Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/4
Y1 - 2020/4
N2 - Lycopene is a carotenoid drug that has demonstrated several properties, including antioxidant and anti-inflammatory activity. The absorption in human body is very low (10–30 % only). In order to increase the bioavailability, lycopene nanoemulsion was formulated and characterized (atomic force microscopy, thermogravimetric analysis dynamic light scattering and differential scanning calorimetry). Also in vitro assay to evaluate the at-binding with MPR1 was performed. Finally, in vivo assay in animals inducted with rheumathoid arthritis were performed. The results showed that the formulated nanolycopene had superior efficacy when compared with the conventional lycopene (not nano-formulated) in inducted animals (rheumatoid arthritis). The results support the use of nanolycopene as an anti-inflammatory agent for rheumatoid arthritis therapy.
AB - Lycopene is a carotenoid drug that has demonstrated several properties, including antioxidant and anti-inflammatory activity. The absorption in human body is very low (10–30 % only). In order to increase the bioavailability, lycopene nanoemulsion was formulated and characterized (atomic force microscopy, thermogravimetric analysis dynamic light scattering and differential scanning calorimetry). Also in vitro assay to evaluate the at-binding with MPR1 was performed. Finally, in vivo assay in animals inducted with rheumathoid arthritis were performed. The results showed that the formulated nanolycopene had superior efficacy when compared with the conventional lycopene (not nano-formulated) in inducted animals (rheumatoid arthritis). The results support the use of nanolycopene as an anti-inflammatory agent for rheumatoid arthritis therapy.
KW - Anti-Inflammatory
KW - Arthritis
KW - Drug
KW - Drug resistance
KW - Nanotechnology
UR - https://www.scopus.com/pages/publications/85078180163
U2 - 10.1016/j.colsurfb.2020.110814
DO - 10.1016/j.colsurfb.2020.110814
M3 - Artículo
C2 - 31982791
AN - SCOPUS:85078180163
SN - 0927-7765
VL - 188
JO - Colloids and Surfaces B: Biointerfaces
JF - Colloids and Surfaces B: Biointerfaces
M1 - 110814
ER -